SeaCrest Wealth Management LLC Invests $32,000 in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

SeaCrest Wealth Management LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,125 shares of the company’s stock, valued at approximately $32,000.

Other hedge funds have also made changes to their positions in the company. Zions Bancorporation N.A. acquired a new stake in shares of Maravai LifeSciences during the first quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its holdings in Maravai LifeSciences by 6,670.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,354 shares of the company’s stock valued at $38,000 after acquiring an additional 1,334 shares in the last quarter. Van ECK Associates Corp acquired a new stake in Maravai LifeSciences in the second quarter valued at approximately $81,000. Point72 Hong Kong Ltd acquired a new stake in Maravai LifeSciences in the first quarter valued at approximately $163,000. Finally, Parametrica Management Ltd acquired a new stake in Maravai LifeSciences in the first quarter valued at approximately $241,000. Institutional investors and hedge funds own 51.02% of the company’s stock.

Maravai LifeSciences Stock Up 1.4 %

MRVI stock opened at $14.35 on Wednesday. The company has a current ratio of 7.22, a quick ratio of 6.68 and a debt-to-equity ratio of 0.62. Maravai LifeSciences Holdings, Inc. has a twelve month low of $13.40 and a twelve month high of $46.29. The company’s 50 day moving average is $19.08 and its two-hundred day moving average is $24.55. The stock has a market cap of $3.66 billion, a P/E ratio of 8.02 and a beta of -0.23.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRVI. Credit Suisse Group reduced their target price on shares of Maravai LifeSciences from $34.00 to $26.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. Bank of America cut shares of Maravai LifeSciences from a “buy” rating to a “neutral” rating and reduced their target price for the company from $32.00 to $17.00 in a report on Thursday, November 3rd. KeyCorp reduced their target price on shares of Maravai LifeSciences from $35.00 to $28.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. TheStreet cut shares of Maravai LifeSciences from a “c-” rating to a “d+” rating in a report on Tuesday, July 26th. Finally, Robert W. Baird reduced their target price on shares of Maravai LifeSciences from $34.00 to $25.00 in a report on Thursday, November 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.33.

Maravai LifeSciences Company Profile

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Read More

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating).

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.